Evercore ISI raised the firm’s price target on Abbott (ABT) to $144 from $142 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have “set the stage for a 2026 Tools play,” the analyst tells investors. In MedTech, the firm’s survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes “have bears watching,” the analyst added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $169 from $162 at Barclays
- 3 Best Dividend Aristocrat Stocks to Buy in 2026
- Unusually active option classes on open December 30th
- Abbott Laboratories: Buy Rating Backed by Volt PFA-Driven Incremental Growth and Strengthening Electrophysiology Position
- Abbott announces FDA approval of Volt PFA System to treat AFib
